Xarelto (Rivaroxaban) is a new alternative for prevention of stroke for patients with atrial fibrillation. With its introduction, we now have the oldest option for patients, Coumadin (Warfarin) and another new anticoagulant treatment Pradaxa (Dabigatran) as options available to reuduce stroke (CVA) risk.  Drs Srivistava and Bilazarian discuss the newest entrant and review the data for patients on the series Matters of the Heart produced by Haverhill Community Television and Pentucket Cardiology.